Moreover, their efficacy against individual components of MACE is not uniform: while GLP-1 RAs reduce the risk of stroke [80, 81], SGLT2is mainly reduce the risk of hospitalisations for heart failure and the risk of adverse kidney outcomes [51, 52, 79, 81–83]. The gene discussed is GLP1R; the disease is heart failure.